文献速递母胎医学

产前外显子组测序及其对围产结局的影响:队列研究

Prenatal exome sequencing and impact on perinatal outcome: cohort study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

本研究回顾性分析2021年3月1日至2022年2月28日转诊至利物浦女子医院胎儿医学单元的72例异常胎儿,其中48例同意 trio 产前外显子组测序(pES),47例成功检测,诊断率为23.4%(11/47)。pES同意组与未提议/未同意组的晚期终止妊娠(≥22周)比例无显著差异(25.0% vs 25.0%,P=1.0),但检出致病变异者晚期终止妊娠比例显著高于无信息结果者(63.6% vs 13.9%,P<0.0009)。

要点

  • pES诊断率为23.4%(11/47),检出致病变异者晚期终止妊娠比例显著高于无信息结果者。
  • pES同意组与未提议/未同意组的晚期终止妊娠比例无显著差异(25.0% vs 25.0%,P=1.0)。
  • 检出致病变异者结果中位周转时间22天(IQR 19-34),长于无信息结果者的14天(IQR 10-15),P<0.0001。

核心结论

  • 本研究显示产前外显子组测序检出致病变异可能影响晚期终止妊娠决策。
  • 作者呼吁临床医生和政策制定者考虑引入更早的异常筛查、制定晚期终止妊娠的可靠指南并确保对夫妇的优化支持。

研究设计与样本

  • 回顾性队列研究,纳入2021年3月1日至2022年2月28日转诊至利物浦女子医院胎儿医学单元的异常胎儿。
  • 共识别72例,48例(三分之二)符合条件女性同意 trio pES,1例因DNA产量低未能进行,最终47例完成检测。
  • 采用Illumina下一代测序平台进行 trio 外显子组测序,评估974个产前相关基因和231个专家评审基因的编码及剪接区域。
  • 使用IBM SPSS version 28.0.1.0进行描述性统计及χ方检验或Fisher精确检验。

主要发现

  • 24例(三分之一)未提议或未同意pES,其中58.3%(14/24)拒绝侵入性检测,41.7%(10/24)仅选择染色体微阵列分析。
  • pES诊断率为23.4%(11/47)。
  • pES同意组与未提议/未同意组的晚期终止妊娠比例无显著差异(25.0%(12/48) vs 25.0%(6/24);P=1.0)。
  • 检出致病变异者晚期终止妊娠比例显著高于pES无信息结果者(63.6%(7/11) vs 13.9%(5/36);P<0.0009)。
  • 检出致病变异者结果中位周转时间22天(IQR 19-34天),长于无信息结果者的14天(IQR 10-15天),P<0.0001。

临床怎么用

  • 作者认为,随着R21路径的持续发展,临床医生和政策制定者应考虑引入更早的异常筛查、制定晚期终止妊娠的可靠指南并确保对夫妇的优化支持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: First, to determine the uptake of prenatal exome sequencing (pES) and the diagnostic yield of pathogenic (causative) variants in a UK tertiary fetal medicine unit following the introduction of the NHS England Rapid Exome Sequencing Service for fetal anomalies testing (R21 pathway). Second, to identify how the decision to proceed with pES and identification of a causative variant affect perinatal outcomes, specifically late termination of pregnancy (TOP) at or beyond 22 weeks' gestation. METHODS: This was a retrospective cohort study of anomalous fetuses referred to the Liverpool Women's Hospital Fetal Medicine Unit between 1 March 2021 and 28 February 2022. pES was performed as part of the R21 pathway. Trio exome sequencing was performed using an Illumina next-generation sequencing platform assessing coding and splice regions of a panel of 974 prenatally relevant genes and 231 expert reviewed genes. Data on demographics, phenotype, pES result and perinatal outcome were extracted and compared. Descriptive statistics and the χ-square or Fisher's exact test were performed using IBM SPSS version 28.0.1.0. RESULTS: In total, 72 cases were identified and two-thirds of eligible women (n = 48) consented to trio pES. pES was not feasible in one case owing to a low DNA yield and, therefore, was performed in 47 cases. In one-third of cases (n = 24), pES was not proposed or agreed. In 58.3% (14/24) of these cases, this was because invasive testing was declined and, in 41.7% (10/24) of cases, women opted for testing and underwent chromosomal microarray analysis only. The diagnostic yield of pES was 23.4% (11/47). There was no overall difference in the proportion of women who decided to have late TOP in the group in which pES was agreed compared with the group in which pES was not proposed or agreed (25.0% (12/48) vs 25.0% (6/24); P = 1.0). However, the decision to have late TOP was significantly more frequent when a causative variant was detected compared with when pES was uninformative (63.6% (7/11) vs 13.9% (5/36); P < 0.0009). The median turnaround time for results was longer in cases in which a causative variant was identified than in those in which pES was uninformative (22 days (interquartile range (IQR), 19-34) days vs 14 days (IQR, 10-15 days); P < 0.0001). CONCLUSIONS: This study demonstrates the potential impact of identification of a causative variant by pES on decision to have late TOP. As the R21 pathway continues to evolve, we urge clinicians and policymakers to consider introducing earlier screening for anomalies, developing robust guidance for late TOP and ensuring optimized support for couples. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Poljak B, Agarwal U, Alfirevic Z, et al. Prenatal exome sequencing and impact on perinatal outcome: cohort study. Ultrasound Obstet Gynecol. 2023. PMID: 36508432. doi:10.1002/uog.26141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。